Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays
The Abbott ID NOW TM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOW TM COVID-19 2.0 facilitates timely diagnosis, enablin...
Saved in:
| Published in | Microbiology spectrum Vol. 13; no. 3; p. e0203324 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
04.03.2025
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The Abbott ID NOW TM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOW TM COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication. |
|---|---|
| AbstractList | Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard for diagnosis but often require a centralized laboratory, making them time-intensive and unsuitable for resource-limited settings. The Abbott ID NOW™ COVID-19 2.0 assay is a rapid point-of-care (POC), isothermal molecular test for qualitative detection of SARS-CoV-2. We prospectively evaluated its clinical performance against three reference rRT-PCR tests: Hologic Panther Fusion, Roche Cobas, and CDC 2019-nCoV RT-PCR Diagnostic Panel. Investigators enrolled 3,530 subjects, with 3,146 evaluable. In symptomatic subjects (
= 914), the test showed a positive percent agreement (PPA) of 91.7% (95% confidence interval [CI]: 87.8, 94.4) and a negative percent agreement (NPA) of 98.4% (95% CI: 97.1, 99.1). The PPA improved with lower cycle threshold (Ct) values: 94.7% (95% CI: 91.2, 97.2) for Ct ≤36, 97.6% (95% CI: 94.5, 99.2) for Ct ≤33, and 99.4% (95% CI: 96.8, 100.0) for Ct ≤30. Discordant results were observed among the three reference rRT-PCR tests across evaluable subjects with suspected COVID-19 infection. For 1,630 cases of symptomatic and asymptomatic subjects suspected of COVID-19, where all three rRT-PCR methods were evaluable, CDC test results differed the most, with 144 discordant results with Roche and 119 with Panther rRT-PCR tests. Roche and Panther test results differed in 67 cases. In summary, the Abbott ID NOW™ COVID-19 2.0 assay can serve as a valuable diagnostic tool in acute symptomatic subjects in point-of-care settings.
The Abbott ID NOW
COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOW
COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication. Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard for diagnosis but often require a centralized laboratory, making them time-intensive and unsuitable for resource-limited settings. The Abbott ID NOW™ COVID-19 2.0 assay is a rapid point-of-care (POC), isothermal molecular test for qualitative detection of SARS-CoV-2. We prospectively evaluated its clinical performance against three reference rRT-PCR tests: Hologic Panther Fusion, Roche Cobas, and CDC 2019-nCoV RT-PCR Diagnostic Panel. Investigators enrolled 3,530 subjects, with 3,146 evaluable. In symptomatic subjects (n = 914), the test showed a positive percent agreement (PPA) of 91.7% (95% confidence interval [CI]: 87.8, 94.4) and a negative percent agreement (NPA) of 98.4% (95% CI: 97.1, 99.1). The PPA improved with lower cycle threshold (Ct) values: 94.7% (95% CI: 91.2, 97.2) for Ct ≤36, 97.6% (95% CI: 94.5, 99.2) for Ct ≤33, and 99.4% (95% CI: 96.8, 100.0) for Ct ≤30. Discordant results were observed among the three reference rRT-PCR tests across evaluable subjects with suspected COVID-19 infection. For 1,630 cases of symptomatic and asymptomatic subjects suspected of COVID-19, where all three rRT-PCR methods were evaluable, CDC test results differed the most, with 144 discordant results with Roche and 119 with Panther rRT-PCR tests. Roche and Panther test results differed in 67 cases. In summary, the Abbott ID NOW™ COVID-19 2.0 assay can serve as a valuable diagnostic tool in acute symptomatic subjects in point-of-care settings.IMPORTANCEThe Abbott ID NOWTM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOWTM COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication. The Abbott ID NOW TM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOW TM COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication. ABSTRACT Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard for diagnosis but often require a centralized laboratory, making them time-intensive and unsuitable for resource-limited settings. The Abbott ID NOW™ COVID-19 2.0 assay is a rapid point-of-care (POC), isothermal molecular test for qualitative detection of SARS-CoV-2. We prospectively evaluated its clinical performance against three reference rRT-PCR tests: Hologic Panther Fusion, Roche Cobas, and CDC 2019-nCoV RT-PCR Diagnostic Panel. Investigators enrolled 3,530 subjects, with 3,146 evaluable. In symptomatic subjects (n = 914), the test showed a positive percent agreement (PPA) of 91.7% (95% confidence interval [CI]: 87.8, 94.4) and a negative percent agreement (NPA) of 98.4% (95% CI: 97.1, 99.1). The PPA improved with lower cycle threshold (Ct) values: 94.7% (95% CI: 91.2, 97.2) for Ct ≤36, 97.6% (95% CI: 94.5, 99.2) for Ct ≤33, and 99.4% (95% CI: 96.8, 100.0) for Ct ≤30. Discordant results were observed among the three reference rRT-PCR tests across evaluable subjects with suspected COVID-19 infection. For 1,630 cases of symptomatic and asymptomatic subjects suspected of COVID-19, where all three rRT-PCR methods were evaluable, CDC test results differed the most, with 144 discordant results with Roche and 119 with Panther rRT-PCR tests. Roche and Panther test results differed in 67 cases. In summary, the Abbott ID NOW™ COVID-19 2.0 assay can serve as a valuable diagnostic tool in acute symptomatic subjects in point-of-care settings.IMPORTANCEThe Abbott ID NOWTM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOWTM COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication. Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard for diagnosis but often require a centralized laboratory, making them time-intensive and unsuitable for resource-limited settings. The Abbott ID NOW™ COVID-19 2.0 assay is a rapid point-of-care (POC), isothermal molecular test for qualitative detection of SARS-CoV-2. We prospectively evaluated its clinical performance against three reference rRT-PCR tests: Hologic Panther Fusion, Roche Cobas, and CDC 2019-nCoV RT-PCR Diagnostic Panel. Investigators enrolled 3,530 subjects, with 3,146 evaluable. In symptomatic subjects ( n = 914), the test showed a positive percent agreement (PPA) of 91.7% (95% confidence interval [CI]: 87.8, 94.4) and a negative percent agreement (NPA) of 98.4% (95% CI: 97.1, 99.1). The PPA improved with lower cycle threshold (Ct) values: 94.7% (95% CI: 91.2, 97.2) for Ct ≤36, 97.6% (95% CI: 94.5, 99.2) for Ct ≤33, and 99.4% (95% CI: 96.8, 100.0) for Ct ≤30. Discordant results were observed among the three reference rRT-PCR tests across evaluable subjects with suspected COVID-19 infection. For 1,630 cases of symptomatic and asymptomatic subjects suspected of COVID-19, where all three rRT-PCR methods were evaluable, CDC test results differed the most, with 144 discordant results with Roche and 119 with Panther rRT-PCR tests. Roche and Panther test results differed in 67 cases. In summary, the Abbott ID NOW™ COVID-19 2.0 assay can serve as a valuable diagnostic tool in acute symptomatic subjects in point-of-care settings. Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard for diagnosis but often require a centralized laboratory, making them time-intensive and unsuitable for resource-limited settings. The Abbott ID NOW™ COVID-19 2.0 assay is a rapid point-of-care (POC), isothermal molecular test for qualitative detection of SARS-CoV-2. We prospectively evaluated its clinical performance against three reference rRT-PCR tests: Hologic Panther Fusion, Roche Cobas, and CDC 2019-nCoV RT-PCR Diagnostic Panel. Investigators enrolled 3,530 subjects, with 3,146 evaluable. In symptomatic subjects (n = 914), the test showed a positive percent agreement (PPA) of 91.7% (95% confidence interval [CI]: 87.8, 94.4) and a negative percent agreement (NPA) of 98.4% (95% CI: 97.1, 99.1). The PPA improved with lower cycle threshold (Ct) values: 94.7% (95% CI: 91.2, 97.2) for Ct ≤36, 97.6% (95% CI: 94.5, 99.2) for Ct ≤33, and 99.4% (95% CI: 96.8, 100.0) for Ct ≤30. Discordant results were observed among the three reference rRT-PCR tests across evaluable subjects with suspected COVID-19 infection. For 1,630 cases of symptomatic and asymptomatic subjects suspected of COVID-19, where all three rRT-PCR methods were evaluable, CDC test results differed the most, with 144 discordant results with Roche and 119 with Panther rRT-PCR tests. Roche and Panther test results differed in 67 cases. In summary, the Abbott ID NOW™ COVID-19 2.0 assay can serve as a valuable diagnostic tool in acute symptomatic subjects in point-of-care settings.Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard for diagnosis but often require a centralized laboratory, making them time-intensive and unsuitable for resource-limited settings. The Abbott ID NOW™ COVID-19 2.0 assay is a rapid point-of-care (POC), isothermal molecular test for qualitative detection of SARS-CoV-2. We prospectively evaluated its clinical performance against three reference rRT-PCR tests: Hologic Panther Fusion, Roche Cobas, and CDC 2019-nCoV RT-PCR Diagnostic Panel. Investigators enrolled 3,530 subjects, with 3,146 evaluable. In symptomatic subjects (n = 914), the test showed a positive percent agreement (PPA) of 91.7% (95% confidence interval [CI]: 87.8, 94.4) and a negative percent agreement (NPA) of 98.4% (95% CI: 97.1, 99.1). The PPA improved with lower cycle threshold (Ct) values: 94.7% (95% CI: 91.2, 97.2) for Ct ≤36, 97.6% (95% CI: 94.5, 99.2) for Ct ≤33, and 99.4% (95% CI: 96.8, 100.0) for Ct ≤30. Discordant results were observed among the three reference rRT-PCR tests across evaluable subjects with suspected COVID-19 infection. For 1,630 cases of symptomatic and asymptomatic subjects suspected of COVID-19, where all three rRT-PCR methods were evaluable, CDC test results differed the most, with 144 discordant results with Roche and 119 with Panther rRT-PCR tests. Roche and Panther test results differed in 67 cases. In summary, the Abbott ID NOW™ COVID-19 2.0 assay can serve as a valuable diagnostic tool in acute symptomatic subjects in point-of-care settings.The Abbott ID NOWTM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOWTM COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication.IMPORTANCEThe Abbott ID NOWTM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOWTM COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication. |
| Author | Siegel, Amy Woods, Christopher W. McKenzie, Mark M. Anderson, Jack G. Jain, Manish Patel, Anand Merchant-Borna, Kian Dennis, Patrick Thoppil, Joby J. Li, Yin Cardona, Jose F. Weinberg, Aaron S. Ebuh, Valentine Strauss, Guy S. Bowie, Aleah Park, Lawrence P. Geller, Steven A. Iglesias-Ussel, Maria D. |
| Author_xml | – sequence: 1 givenname: Maria D. orcidid: 0000-0002-3679-9681 surname: Iglesias-Ussel fullname: Iglesias-Ussel, Maria D. – sequence: 2 givenname: Aleah surname: Bowie fullname: Bowie, Aleah – sequence: 3 givenname: Jack G. surname: Anderson fullname: Anderson, Jack G. – sequence: 4 givenname: Yin surname: Li fullname: Li, Yin – sequence: 5 givenname: Lawrence P. surname: Park fullname: Park, Lawrence P. – sequence: 6 givenname: Jose F. surname: Cardona fullname: Cardona, Jose F. – sequence: 7 givenname: Patrick surname: Dennis fullname: Dennis, Patrick – sequence: 8 givenname: Valentine surname: Ebuh fullname: Ebuh, Valentine – sequence: 9 givenname: Steven A. surname: Geller fullname: Geller, Steven A. – sequence: 10 givenname: Manish surname: Jain fullname: Jain, Manish – sequence: 11 givenname: Mark M. surname: McKenzie fullname: McKenzie, Mark M. – sequence: 12 givenname: Kian surname: Merchant-Borna fullname: Merchant-Borna, Kian – sequence: 13 givenname: Anand surname: Patel fullname: Patel, Anand – sequence: 14 givenname: Amy surname: Siegel fullname: Siegel, Amy – sequence: 15 givenname: Guy S. surname: Strauss fullname: Strauss, Guy S. – sequence: 16 givenname: Joby J. surname: Thoppil fullname: Thoppil, Joby J. – sequence: 17 givenname: Aaron S. surname: Weinberg fullname: Weinberg, Aaron S. – sequence: 18 givenname: Christopher W. surname: Woods fullname: Woods, Christopher W. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39932292$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks9u1DAQxiNURMvSB-CCfOSSxZ7Ym-SEqi1_VqpYVK3gaE284zarJA62g9Qr6pP00XgS3G5btQdO9ow__zT65nudHQxuoCx7K_hcCKg-hJFM9FM_58CLIgf5IjsCsVA5l3V58OR-mB2HsOOcC8EVKHiVHRZ1XQDUcJT9WXbt0Brs2EjeOt_jYIg5y06axsXIVqfs2_rn3-sbtlz_WJ3momYw58zj2G5Z7zoyU4eeja4dYu5sbtATixQiM64fU7Fl0bF46YmYJ-zy2PbEzjf59-U5wxDwKrzJXlrsAh3fn7Ns8_nTZvk1P1t_WS1PznKUqoy5BFMtpG0MEBRWEPKFrUuBUEJjqiIVFgoDIBp-2wCpFK8sGakaqhpRzLLVHrt1uNOjb3v0V9phq-8azl9o9LE1HWlh-ZZEkdzilQSFWMoEl9YqVVUcIbE-7lnj1PS0NTREj90z6POXob3UF-63FqIqyzq5P8ve3xO8-zUlv3TfBkNdhwO5KegibU8KWUqVpPO9FEMPeucmPySbtOD6Ngf6IQf6LgcaZPrw7ul0j2M9bD0JxF5gvAvBk32U_B_6DwHKwhw |
| Cites_doi | 10.1016/S0140-6736(21)02346-1 10.1093/infdis/jiab107 10.1056/NEJMoa2008457 10.1016/S2666-5247(20)30172-5 10.3390/biom10091312 10.1002/14651858.CD013705.pub3 10.1136/bmj.m3862 10.2807/1560-7917.ES.2020.25.32.2001483 10.1177/2632010X241228053 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Iglesias-Ussel et al. Copyright © 2025 Iglesias-Ussel et al. 2025 Iglesias-Ussel et al. |
| Copyright_xml | – notice: Copyright © 2025 Iglesias-Ussel et al. – notice: Copyright © 2025 Iglesias-Ussel et al. 2025 Iglesias-Ussel et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1128/spectrum.02033-24 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ : directory of open access journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2165-0497 |
| Editor | Bello, Alexander |
| Editor_xml | – sequence: 1 givenname: Alexander surname: Bello fullname: Bello, Alexander |
| ExternalDocumentID | oai_doaj_org_article_1f0de1305208425aa749f24ff55880a2 PMC11877999 spectrum02033-24 39932292 10_1128_spectrum_02033_24 |
| Genre | Journal Article Comparative Study |
| GroupedDBID | 53G AAGFI AAUOK AAYXX ADBBV AGVNZ ALMA_UNASSIGNED_HOLDINGS CITATION EJD FF~ FRP GROUPED_DOAJ H13 M~E OK1 RPM RSF CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-a457t-42c864fbc2e23f1ea06f971a272bc836f9f23c221b02bc8245508fec45be8b13 |
| IEDL.DBID | AAUOK |
| ISSN | 2165-0497 |
| IngestDate | Wed Aug 27 01:31:18 EDT 2025 Thu Aug 21 18:27:16 EDT 2025 Fri Jul 11 05:17:17 EDT 2025 Tue Mar 04 23:41:10 EST 2025 Thu May 08 05:29:48 EDT 2025 Tue Jul 01 05:24:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | COVID-19 SARS-CoV-2 rapid testing POC nicking endonuclease amplification reaction (NEAR) isothermal ID NOW rRT-PCR |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a457t-42c864fbc2e23f1ea06f971a272bc836f9f23c221b02bc8245508fec45be8b13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Yin Li is a Senior Principal Biostatistician at Abbott Laboratories. Kian Merchant-Borna has served on scientific advisory boards for Abbott Diagnostics unrelated to the submitted work. Each author's institution received financial support for the performance of the study. Christopher W. Woods is employed and holds equity in Biomeme. He is on the advisory board for FHI Clinical and is a member of the Board of Directors for Global Health Innovation Alliance Accelerator. |
| ORCID | 0000-0002-3679-9681 |
| OpenAccessLink | https://journals.asm.org/doi/10.1128/spectrum.02033-24 |
| PMID | 39932292 |
| PQID | 3165414745 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1f0de1305208425aa749f24ff55880a2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11877999 proquest_miscellaneous_3165414745 asm2_journals_10_1128_spectrum_02033_24 pubmed_primary_39932292 crossref_primary_10_1128_spectrum_02033_24 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-03-04 |
| PublicationDateYYYYMMDD | 2025-03-04 |
| PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Microbiology spectrum |
| PublicationTitleAbbrev | Spectrum |
| PublicationTitleAlternate | Microbiol Spectr |
| PublicationYear | 2025 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_17_2 e_1_3_3_9_2 e_1_3_3_16_2 e_1_3_3_13_2 e_1_3_3_12_2 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_2_2 e_1_3_3_4_2 e_1_3_3_11_2 e_1_3_3_3_2 e_1_3_3_10_2 B14 B15 Peeling, RW, Heymann, DL, Teo, YY, Garcia, PJ (B4) 2022; 399 Cevik, M, Tate, M, Lloyd, O, Maraolo, AE, Schafers, J, Ho, A (B11) 2021; 2 Dinnes, J, Sharma, P, Berhane, S, van Wyk, SS, Nyaaba, N, Domen, J, Taylor, M, Cunningham, J, Davenport, C, Dittrich, S, Emperador, D, Hooft, L, Leeflang, MM, McInnes, MD, Spijker, R, Verbakel, JY, Takwoingi, Y, Taylor-Phillips, S, Van den Bruel, A, Deeks, JJ (B6) 2022; 7 B2 B5 B7 B8 B9 Owusu, D, Pomeroy, MA, Lewis, NM, Wadhwa, A, Yousaf, AR, Whitaker, B, Dietrich, E, Hall, AJ, Chu, V, Thornburg, N (B12) 2021; 224 Elrashdy, F, Redwan, EM, Uversky, VN (B1) 2020; 10 Singanayagam, A, Patel, M, Charlett, A, Lopez Bernal, J, Saliba, V, Ellis, J, Ladhani, S, Zambon, M, Gopal, R (B16) 2020; 25 Roknuzzaman, A, Sarker, R, Shahriar, M, Mosharrafa, RA, Islam, MR (B3) 2024; 17 Cevik, M, Kuppalli, K, Kindrachuk, J, Peiris, M (B10) 2020; 371 Arons, MM, Hatfield, KM, Reddy, SC, Kimball, A, James, A, Jacobs, JR, Taylor, J, Spicer, K, Bardossy, AC, Oakley, LP (B13) 2020; 382 |
| References_xml | – ident: e_1_3_3_5_2 doi: 10.1016/S0140-6736(21)02346-1 – ident: e_1_3_3_13_2 doi: 10.1093/infdis/jiab107 – ident: e_1_3_3_8_2 – ident: e_1_3_3_6_2 – ident: e_1_3_3_14_2 doi: 10.1056/NEJMoa2008457 – ident: e_1_3_3_3_2 – ident: e_1_3_3_9_2 – ident: e_1_3_3_10_2 – ident: e_1_3_3_15_2 – ident: e_1_3_3_12_2 doi: 10.1016/S2666-5247(20)30172-5 – ident: e_1_3_3_2_2 doi: 10.3390/biom10091312 – ident: e_1_3_3_7_2 doi: 10.1002/14651858.CD013705.pub3 – ident: e_1_3_3_16_2 – ident: e_1_3_3_11_2 doi: 10.1136/bmj.m3862 – ident: e_1_3_3_17_2 doi: 10.2807/1560-7917.ES.2020.25.32.2001483 – ident: e_1_3_3_4_2 doi: 10.1177/2632010X241228053 – ident: B2 article-title: WHO director-general’s opening remarks at the media briefing on COVID-19 . 2020 . https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . – volume: 382 start-page: 2081 year: 2020 end-page: 2090 ident: B13 article-title: Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility publication-title: N Engl J Med doi: 10.1056/NEJMoa2008457 – ident: B8 article-title: Abbott . 2023 . Predicted impact of variants on Abbott’s SARS-CoV-2/COVID-19 diagnostic tests-technical brief – volume: 7 year: 2022 ident: B6 article-title: Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD013705.pub3 – volume: 25 start-page: 1 year: 2020 ident: B16 article-title: Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.32.2001483 – volume: 10 year: 2020 ident: B1 article-title: Why COVID-19 transmission is more efficient and aggressive than viral transmission in previous coronavirus epidemics? publication-title: Biomolecules doi: 10.3390/biom10091312 – ident: B7 article-title: Abbott point of care . 2024 . Available from : https://www.globalpointofcare.abbott/us/en/product-details/id-now.html . Retrieved 5 Dec 2024 . – volume: 371 year: 2020 ident: B10 article-title: Virology, transmission, and pathogenesis of SARS-CoV-2 publication-title: BMJ doi: 10.1136/bmj.m3862 – volume: 2 start-page: e13 year: 2021 end-page: e22 ident: B11 article-title: SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis publication-title: Lancet Microbe doi: 10.1016/S2666-5247(20)30172-5 – ident: B5 article-title: Who is at high risk for severe coronavirus disease? 2024 . Johns Hopkins Medicine . Available from : https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-and-covid19-who-is-at-higher-risk – volume: 17 year: 2024 ident: B3 article-title: The WHO has declared COVID-19 is no longer a pandemic-level threat: a perspective evaluating potential public health impacts publication-title: Clin Pathol doi: 10.1177/2632010X241228053 – volume: 224 start-page: 1362 year: 2021 end-page: 1371 ident: B12 article-title: Persistent SARS-CoV-2 RNA shedding without evidence of infectiousness: a cohort study of individuals with COVID-19 publication-title: J Infect Dis doi: 10.1093/infdis/jiab107 – ident: B14 article-title: Nucleic acid amplification testing (e.g. RT-PCR) . 2023 . Available from : https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/RT-pcr-testing – ident: B15 article-title: Real-time PCR: understanding Ct - US . – ident: B9 article-title: Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing | COVID-19 | CDC . 2024 . Available from : https://www.cdc.gov/covid/hcp/clinical-care/clinical-specimen-guidelines.html . Retrieved 5 Dec 2024 . – volume: 399 start-page: 757 year: 2022 end-page: 768 ident: B4 article-title: Diagnostics for COVID-19: moving from pandemic response to control publication-title: Lancet doi: 10.1016/S0140-6736(21)02346-1 |
| SSID | ssj0001105252 |
| Score | 2.323015 |
| Snippet | The Abbott ID NOW TM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care... Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard... ABSTRACT Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference... |
| SourceID | doaj pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0203324 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Child COVID-19 COVID-19 - diagnosis COVID-19 Nucleic Acid Testing - methods COVID-19 Testing - methods Female Humans ID NOW isothermal Male Middle Aged Molecular Diagnostic Techniques - methods POC Point-of-Care Systems Point-of-Care Testing Prospective Studies Real-Time Polymerase Chain Reaction - methods Research Article rRT-PCR SARS-CoV-2 SARS-CoV-2 - genetics SARS-CoV-2 - isolation & purification Sensitivity and Specificity Special Series: Laboratory Equity Virology Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ : directory of open access journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZlodBL6bvbFyoUCgUl9khe2cd005AUmpSwbXMTki2Rhay9ZJ1DriG_pD-tv6Qzsp3ultJeerQs20Izkr7xPD7G3jgvQVsLwpUaDRRQQTjnJwjkJLhK68IllJz86XCy_0V9PMlO1qi-KCasKw_cTdx2GpLK40abQUIeI2u1KgK-MmQZqp6Nuy-eeWvGVPy7khI_G_RuTNyDt2Pi4vnFYotcb1JQhvvIrhawcR7Fsv1_wpq_h0yunUF799jdHjzynW7Q99ktXz9gtzs6ycuH7Kov8nnGl7_SAXgT-E4kDOMHu_zw6NuP6-98evT1YFekBYethJ_b5bzii4Enly-bed2KJgiKCuMIRVs-RKrztuEtSt9zxJpngojp-fFMfJ4ecwTh9nL1iM32Psym-6LnWBBWZbpF6ZT5RAVXggcZUm-TSSh0akGDK3OJFwFkCZC6hBqAkqDz4EuVOZ-7VD5mo7qp_VPGVaXJq5hXZGOWKrcerMsyWZYu5M5nY_aW5tv0a2RlovkBuRkkY6JkDKgxezeIxCy7mht_6_yehHbTkcplxwZUItMrkfmXEo3Z60HkBpcX-Uxs7ZuLlZFpJErXCsf_pFOBm08RtgMo8Ol8Qzk2xrJ5p56fxhLeRPKuEZs_-x-jf87uALESU2ScesFGOD_-JUKl1r2Kq-InsMUQxQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39932292 https://journals.asm.org/doi/10.1128/spectrum.02033-24 https://www.proquest.com/docview/3165414745 https://pubmed.ncbi.nlm.nih.gov/PMC11877999 https://doaj.org/article/1f0de1305208425aa749f24ff55880a2 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZGJyRe0LiuXCYjISEhuSQndu08lo5pA7GiqYO9WXZii0prUq3Zw14nfgk_jV_CsZt0FE2Ix9ix7Pjz5XOOz_kIeW1dBtIYYLaQeEAB7pm1bohELgNbSpnbJDgnfz4eHp7yj2fibIsMO1-YtgeXA7OcR0P-emaDehedDy8u54NgPssY8DtkW0DOkx7ZHo1OJ59u_q6kQZ8NWjPmrWVxDcY6YGM_imH7b-Oaf1-Z_GMPOtgh91vySEcrtB-QLVc9JHdXcpJXj8h1G-TznC5u3AFo7ekoCobRo316PPn268dPOp58PdpnaU5hkNALs5iVdN7p5NJFPasaVnsWboVRpKIN7W6q06amDaLvKHLNcxaE6enJlH0Zn1Ak4eZq-ZhMDz5Mx4es1VhghgvZIDqFGnJvC3CQ-dSZZOhzmRqQYAuV4YOHrABIbRISIDhBK-8KLqxTNs2ekF5VV26XUF7KYFVUZThjFlwZB8YKkRWF9co60SdvQn_rDmEdjx-gdIeMjsho4H3ytoNEL1YxN_718vsA2vrFEC47JuDg0e3s06lPSoe7tYAkmB2NkRy_i3svBK5fBvrkVQe5xukVbCamcvXlUmdpFEqXHNv_dDUE1lUFbgeQY2m1MTg22rKZU82-xxDeQeRdIjd_9t-d8pzcgyA9HK6_8Rekh5nuJfKhxu61g38v_k_4Dfs1Ckg |
| linkProvider | American Society for Microbiology |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZgE2IviDvlaiQkJKSU5MSp3cfSMbVsa9HUwd4sO7FFpzapluxhr4hfwk_jl3BOmmwUTYjHJI6c-Jxjf_a5fIy9sS4GaQwENpW4QQHhA2tdD4FcDDaTsm9DSk4-nPRGx-LTSXLSRFVSLswp8fIuyq4pl7UfnwybDqIbPkL1vk5APDtfdsmFFgcgbrJt8h2idm8PBsfT_asTlog42qBxZV77Ls7D2BFsrEl16f7r8ObfYZN_rEN7d9mdBkDywVri99gNl99nt9aUkhcP2Pem0OeCr65SAnjh-aAmDePjXT6Zfv314ycfTr-Md4Ooz6Eb8jOzmmd82XLl8lUxz6ug8AFFhnGEoxVvo9V5VfAKNcBxxJuLgMjp-dEs-Dw84gjEzUX5kM32Ps6Go6DhWQiMSGSFEkpVT3ibgoPYR86EPd-XkQEJNlUxXniIU4DIhnQDKBFaeZeKxDplo_gR28qL3D1hXGSSPIsqo31mKpRxYGySxGlqvbIu6bC3NN66sZNS11sQULqVjK4lo0F02LtWJHq1rrvxr8YfSGiXDalkdn0DNUg3FqgjH2YOV-wEQnI9GiMF_pfwPklwDjPQYa9bkWs0MfKbmNwV56WOo5osXQr8_sdrFbjsivAdQB_fVhvKsfEtm0_y-be6jDcRvUvE50__e1Besduj2eGBPhhP9p-xHSAqYgqHE8_ZFjZ0LxAfVfZlYwi_AWYBDbY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZgE4gXxJ1yNRISEpJLcuLU7mNpqVYG7TR1sDfLTmxRaU2qNXvYK-KX8NP4JZyTJhtFE-Ixji07Psf255zLx9hr5xNQ1oJwmcILCsggnPM9BHIJuFypvosoOPnztLd3JD8ep8eNVyXFwjQzuO7a9bI25NPKXuWh4SPU7-oAxNOzZZdMaIkAeZ3tkrEKdXx3MDia7V_-YYmJow0aU-aVbXEfxn5g60yqU_dfhTf_dpv84xwa32G3GwDJBxuJ32XXfHGP3dhQSp7fZ9-bRJ8nfHUZEsDLwAc1aRifjPh09vXXj598OPsyGYm4z6Eb8VO7WuR82XLl8lW5KCpRBkGeYRzhaMVbb3VelbxCDfAc8eaJIHJ6fjgXB8NDjkDcnq8fsPn4w3y4JxqeBWFlqiqUUKZ7MrgMPCQh9jbqhb6KLShwmU7wIUCSAcQuogKgQGgdfCZT57WLk4dspygL_5hxmSuyLOqc7pmZ1NaDdWmaZJkL2vm0w97QfJtWyqa-goA2rWRMLRkDssPetiIxq03ejX9Vfk9Cu6hIKbPrAlQg06xAE4co93hipxCR6dFaJfG7ZAhpinuYhQ571Yrc4BIju4ktfHm2Nklck6UrieN_tFGBi64I3wH0sbXeUo6tsWy_KRbf6jTeRPSuEJ8_-e9JecluHozG5tNkuv-U3QJiIiZvOPmM7WA9_xzhUeVeNOvgNztUDVI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+performance+of+Abbott+ID+NOW%E2%84%A2+COVID-19+2.0+rapid+molecular+point-of-care+test+compared+to+three+real-time+RT-PCR+assays&rft.jtitle=Microbiology+spectrum&rft.au=Iglesias-Ussel%2C+Maria+D&rft.au=Bowie%2C+Aleah&rft.au=Anderson%2C+Jack+G&rft.au=Li%2C+Yin&rft.date=2025-03-04&rft.eissn=2165-0497&rft.volume=13&rft.issue=3&rft.spage=e0203324&rft_id=info:doi/10.1128%2Fspectrum.02033-24&rft_id=info%3Apmid%2F39932292&rft.externalDocID=39932292 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-0497&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-0497&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-0497&client=summon |